FDA Grants Priority Review to Genentech’s HEMLIBRA (emicizumab-kxwh) for People with Hemophilia A without Factor VIII Inhibitors Genetics Investing
Dacomitinib Shows More than Seven-Month Improvement in Overall Survival Compared to an Established Therapy in Advanced NSCLC with EGFR-Activating Mutations Pharmaceutical Investing
LYNPARZA (olaparib) in Combination with Abiraterone Delayed Disease Progression in Metastatic Castration-Resistant Prostate Cancer Pharmaceutical Investing
Deciphera Pharmaceuticals Announces Proposed Public Offering of Common Stock Pharmaceutical Investing
TESARO Announces Collaboration to Evaluate ZEJULA in Combination With Anti-PD-L1 Cancer Immunotherapy and MEK Inhibitor in Platinum-Sensitive Ovarian Cancer Pharmaceutical Investing
Summit Therapeutics Reports Financial Results for the First Quarter Ended 30 April 2018 and Operational Progress Pharmaceutical Investing
Protalix BioTherapeutics Announces Additional Positive Results from Final Analysis of the Phase II Clinical Trial of OPRX-106 for the Treatment of Ulcerative Colitis Biotech Investing
Axsome Therapeutics Initiates Phase 2 Trial of AXS-05 in Major Depressive Disorder Pharmaceutical Investing
Kite Announces Initial Results From a Phase 1 Study of T Cell Receptor (TCR) Cell Therapy in HPV-16-Positive Solid Tumors Pharmaceutical Investing
Opdivo (nivolumab) 3 mg/kg Demonstrates Sustained, Superior Recurrence-Free Survival Versus Yervoy (ipilimumab) 10 mg/kg for Broad Range of Patients with Resected Stage III or IV Melanoma Pharmaceutical Investing
